MBX 675

Drug Profile

MBX 675

Alternative Names: MBX 675 Program; Natural Products Programme - Metabolex

Latest Information Update: 23 Mar 2007

Price : $50

At a glance

  • Originator Metabolex
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 21 Aug 2003 MBX 675 is undergoing optimisation with Metabolex
  • 05 Jul 2001 Preclinical development for Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top